Healthcare >> Analyst Interviews >> May 3, 2004
LEI ZHONG is a Senior Biotechnology Analyst at Rodman & Renshaw. Prior
to joining Rodman, Dr. Zhong was an Emerging Equity Analyst in
Biotechnology with UBS Investment Bank where he covered large and mid-
cap biotechnology companies. Dr. Zhong obtained his PhD in Life Sciences
from the Rockefeller University in New York where he conducted
researches in the areas of immunology, virology, molecular biology and
structural biology. Dr. Zhong is a lead author of numerous peer-
reviewed scientific journals and a speaker at academic research
conferences at both national and international levels. He is focused on
mid-cap biotechnology companies with novel technologies and early or
late stage clinical products under development. Profile
Renshaw?
Dr. Zhong: I joined Rodman about a month and a half ago, and as we speak
I don't have any official coverage.
